DYRK1A and prostate cancer: Prostate-cancer-cell-derived EVs loaded with miR-378a-3p accelerated osteolysis by targeting the Dyrk1a/Nfatc1 axis to upregulate ANGPTL2 expression and secretion, thereby promoting PMN formation and enhancing prostate cancer metastasis.